Brad Osborne

Brad Osborne is an executive with 20 years of extensive finance and accounting experience. Prior to joining Melt Pharmaceuticals as Chief Financial Officer in February 2022, Mr. Osborne worked for 10 years with Precigen, Inc. (formerly Intrexon Corporation), a Nasdaq-listed discovery and clinical-stage biopharmaceutical company, having served the last five years as Vice President, Finance and Accounting. During his tenure with Precigen, he managed all finance and accounting activities related to Precigen’s initial public offering, multiple private and public equity and debt capital raises, SEC reporting and compliance, mergers and acquisitions, divestitures, and budgeting.

Mr. Osborne previously served as Accounting Director, Portfolio Investments, for Third Security, LLC, a manager of a portfolio of biotechnology companies, and he began his career with public accounting firm KPMG LLP. Mr. Osborne has a B.S. in Accounting from Virginia Tech and is a certified public accountant.